Deena Fayyad

Ms. Deena Fayyad

University of Michigan–Ann Arbor, Ann Arbor, Michigan, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2026 in International Journal of Dermatology
Verified
Journal Article
Open access
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
IGIsha Gandhi
Isha Gandhi
RARobert Adler
Robert Adler
DFDeena Fayyad
Deena Fayyad
PBPerya Bhagchandani
Perya Bhagchandani
SKShawn G. Kwatra
Shawn G. Kwatra
Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment. This systematic review examines the diagnostic work‐up and therapeutic approaches for CPUO, evaluating the quality of treatment studies using the Strength of Recommendation Taxonomy (SORT) algorithm. Our paper also uniquely integrates a review of potential pathogenic mechanisms. A comprehensive literature search was conducted in PubMed, EMBASE, Ovid MEDLINE, and Cochrane databases through September 2025 using terms including “CPUO,” “chronic idiopathic pruritus,” and “pruritus of unknown origin.” Studies discussing pathogenesis, diagnostic strategies, or treatment were included. Treatment interventions were assessed based on the SORT algorithm. Of 228 identified records, 52 met inclusion criteria: 18 addressing pathogenesis, 5 discussing competing etiological hypotheses, 3 focusing on diagnostic work‐up, 23 on treatment, and 3 on non‐pharmacological therapies. CPUO pathogenesis appears multifactorial, involving Th2 dysregulation, neurogenic factors (JAK1, GRPR, TRPV4), metabolic alterations, and aging‐related immune changes. Current diagnostic approaches emphasize exclusion of systemic, dermatologic, and neurologic causes. Treatment options include topical agents (calcineurin inhibitors, capsaicin), systemic immunomodulators (JAK inhibitors, dupilumab, nemolizumab), neuromodulators (gabapentin, pregabalin), and phototherapy. However, available treatment studies are of low quality, with few randomized controlled trials (RCTs). CPUO remains a challenging condition with unclear pathophysiology and limited high‐quality therapeutic evidence. Further research, particularly RCTs, is needed to establish evidence‐based management strategies.

18 April 2022 in Biochem
Verified
Journal Article
Open access
PDF file
DFDeena Fayyad
Deena Fayyad
JKJessica L Kelts
Jessica L Kelts
TNTristan Nielson
Tristan Nielson
IEIbiere Lovelyn Epelle
Ibiere Lovelyn Epelle
NMNicodemus C. Monear
Nicodemus C. Monear
BXBesa Xhabija
Besa Xhabija
Objectives: The emergence of coronavirus disease 2019 (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global health calamity unprecedented in the modern world. The disease spread worldwide, and to date, there have been over 230 million confirmed cases of COVID-19, including approximately 4.7 million deaths. Mutant variants of the virus have raised concerns about additional pandemic waves and threaten to reverse our progress thus far to limit the spread of the virus. These variants include Alpha, Beta, and Delta (first reported in December 2020 in the United Kingdom, South Africa, and India, respectively) and Gamma (reported in January 2021 in Brazil). In some cases, countries have even reported a rise in daily cases higher than the first wave in March 2020. Given the rapidly evolving nature of COVID-19 and subsequent new findings and updates each day, this review article aims to comprehensively summarize the etiology, pathophysiology, and clinical features of SARS-CoV-2 infection. Methods: A systematic review of the literature was performed in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to gain insight into the transmissibility, pathogenesis, entry factors, and immune response of COVID-19. Specifically, Pubmed and Google Scholar databases were searched to identify any relevant articles. References within the included articles were reviewed. Published articles related to search criteria from the onset of the COVID-19 pandemic to March 2022 were included. Results: Viral transmissibility is predominantly affected by the modes of transmission, various mutations on the nucleocapsid protein and endoRNAse, gender, age, and other factors. The pathophysiological mechanism is generally unknown, although the clinical manifestations such as headache, loss of smell and taste, vomiting, diarrhea, multiorgan failure, and dermatological and cardiovascular complications are well documented. The progression of infection depends on the immunopathological response and the innate/adaptive immunity. Conclusion: Our review has summarized the latest knowledge about SARS-CoV2. However, as the pandemic continues to spread across the continents, there is an urgent need for more research on potentially emerging coronaviruses and the development of a universal coronaviruses vaccine to put the pandemic behind us.

18 October 2025 in JID Innovations
Verified
Journal Article
Open access
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
SBShrey Bhatt
Shrey Bhatt
KVKavita Vats
Kavita Vats
SYSelina M. Yossef
Selina M. Yossef
DGDavies Gage
Davies Gage
SKShawn G. Kwatra
Shawn G. Kwatra
Prurigo nodularis (PN) is a chronic, neuroimmune-driven skin disease characterized by intensely pruritic nodules and marked impairment in QOL. Although PN shares inflammatory features with atopic dermatitis and psoriasis, its underlying pathogenesis remains poorly defined. In this study, we performed NanoString-based transcriptomic profiling on lesional skin biopsies from patients with PN (n = 26), those with atopic dermatitis (n = 25), those with psoriasis (n = 15), and healthy controls (n = 12) using a custom neuroinflammation-focused panel. PN demonstrated a unique molecular signature involving neuroimmune activation (TMEM119, S100A10), extracellular matrix remodeling (matrix metalloproteinase 14 gene MMP14, COL6A3), and fibrotic signaling (TGFBR1, ITGB5), with IL-6 and MAPK12 as key inflammatory mediators. Compared with atopic dermatitis, PN displayed reduced T helper 2 signaling but greater neuroinflammatory and fibrotic activity. Relative to psoriasis, PN lacked T helper 17–driven hyperproliferation but showed macrophage and extracellular matrix activation. STRING network analysis also revealed IL-6 and TGF-β signaling as central hubs linking neuroinflammation and fibrosis. These findings establish PN as a distinct inflammatory skin disease at the intersection of neuroimmune dysregulation and tissue remodeling. Our results highlight key pathways that may guide precision therapies beyond current T helper 2–targeted treatments, supporting the development of IL-6, TGF-β, and Jak/signal transducer and activator of transcription–directed strategies in PN. This transcriptomic analysis establishes a framework to guide mechanistic and therapeutic investigations in PN.

25 August 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
DFDeena Fayyad
Deena Fayyad
NDNicholas Dol
Nicholas Dol
IGIsha Gandhi
Isha Gandhi
CFChase Fishman
Chase Fishman
SFSteven Fishman
Steven Fishman

6 August 2026 in Archives of Dermatological Research
Verified
Journal Article
Closed access
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
DFDeena Fayyad
Deena Fayyad
DGDavies Gage
Davies Gage
SSShahin Shahsavari
Shahin Shahsavari
KKKristin Lee Khan
Kristin Lee Khan
SKShawn G. Kwatra
Shawn G. Kwatra